Study: NCT03311412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.